Abstract：
BACKGROUND:Patients with multiple primary lung cancers increasingly receive multiple courses of stereotactic body radiotherapy (SBRT). We aimed to clarify the efficacy and safety of such treatments. PATIENTS AND METHODS:We reviewed a prospective lung SBRT database of patients treated for stage I non-small-cell lung cancer between June 2004 and December 2015. RESULTS:A total of 374 patients received a single course of SBRT, 14 received synchronous SBRT, 48 received metachronous SBRT alone, and 108 received surgery and metachronous SBRT. Median follow-up was 37.0 months for survivors. Patients who received a single course had a 3-year overall survival (OS) of 54.2% (95% confidence interval [CI], 48.8-59.3), 3-year freedom from progression (FFP) of 67.3% (95% CI, 60.9-72.9), and grade 3 or higher toxicity of 3.5%. Compared to single-course patients, patients receiving metachronous SBRT alone and patients receiving surgery and metachronous SBRT had improved OS (79.7% [95% CI, 64.4-88.9%], P < .0001 and 95.4% [95% CI, 89.2-98.0%], P < .0001, respectively) and FFP (85.8% [95% CI, 70.7-93.5], P = .03 and 95.4% [95% CI, 89.2-98.0%], P < .0001, respectively). Patients receiving synchronous SBRT had similar OS (46.4% [95% CI, 19.3-69.9%], P = .75) and similar FFP (57.5% [95% CI, 25.3-80.0%], P = .17) as single-course patients. There were no significant differences in rates of grade 3 or higher toxicity or of grade 1 or higher toxicity between single-course patients and the other groups. CONCLUSION:Patients who received either synchronous or metachronous SBRT had no significant detriment in OS or toxicity compared to single-course patients. This supports the use of SBRT in patients with multiple primary lung cancers.
journal_name
Clin Lung Cancerjournal_title
Clinical lung cancerauthors
Nikitas J,DeWees T,Rehman S,Abraham C,Bradley J,Robinson C,Roach Mdoi
10.1016/j.cllc.2018.10.010subject
Has Abstractpub_date
2019-03-01 00:00:00pages
107-116issue
2eissn
1525-7304issn
1938-0690pii
S1525-7304(18)30294-8journal_volume
20pub_type
杂志文章abstract：BACKGROUND:The programmed death 1/programmed death-ligand 1 (PD-L1) pathway reportedly is as an important factor determining effects of immunotherapy; however, its prognostic impact is controversial, and its association with the surrounding immune microenvironment has not yet been elucidated. PATIENTS AND METHODS:We r...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2020.01.013
更新日期：2020-07-01 00:00:00
abstract：:The treatment landscape of small-cell lung cancer is rapidly evolving. Results of the first-line randomized trial comparing etoposide/carboplatin/placebo with etoposide/carboplatin/atezolizumab (IMpower-133) were recently published, showing a longer progression-free survival and overall survival for patients receiving...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.1016/j.cllc.2018.12.019
更新日期：2019-05-01 00:00:00
abstract：:This study was designed as a multicenter, randomized, double-blind, placebo-controlled trial. Patients were randomized by center to placebo (16 patients, 31%), oral bexarotene 300 mg/m2/day (21 patients, 40%), or oral bexarotene 600 mg/m2/day (15 patients, 29%) following demonstration of stable or responsive disease a...
journal_title：Clinical lung cancer
pub_type： 临床试验,杂志文章,随机对照试验
doi：10.3816/clc.2001.n.005
更新日期：2001-02-01 00:00:00
abstract：:This clinical trial summary provides the background and rationale for a randomized trial examining the benefits of pemetrexed/ cisplatin chemotherapy combined with radiation followed by consolidation pemetrexed in patients with unresectable stage IIIA/B non-small-cell lung cancer. The rationale for the selection of th...
journal_title：Clinical lung cancer
pub_type： 杂志文章,随机对照试验
doi：10.3816/CLC.2009.n.027
更新日期：2009-05-01 00:00:00
abstract：BACKGROUND:The primary objective of this study was to evaluate the association between radiation sensitivity of the lungs and candidate single nucleotide polymorphisms (SNP) in genes implicated in radiation-induced toxicity. METHODS:Patients with lung cancer who received radiation therapy (RT) had pre-RT and serial po...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2012.10.006
更新日期：2013-05-01 00:00:00
abstract：BACKGROUND:The optimal treatment strategy for locoregional recurrences developing after surgical resection in patients with non-small-cell lung cancer (NSCLC) is yet to be clearly established. PATIENTS AND METHODS:To investigate the efficacy and safety of radiotherapy (RT) and chemoradiotherapy (CRT), we reviewed the ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2017.05.005
更新日期：2017-11-01 00:00:00
abstract：:Metastatic non-small-cell lung cancer is generally not considered to be curable, and the overall 5-year survival rate is less than 1%. Despite this poor prognosis, palliative chemotherapy can increase time and quality of life in the advanced-disease setting. New chemotherapy treatments and targeted therapies are avail...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2011.06.007
更新日期：2011-11-01 00:00:00
abstract：BACKGROUND:Hormesis is a favorable biological response to low toxin exposure. In the case of radiation, large doses are carcinogenic, but low doses might be protective. In the current study, we analyzed lung cancer incidence in high-impact radiation states where nuclear testing occurred and compared it with lung cancer...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2014.09.010
更新日期：2015-03-01 00:00:00
abstract：BACKGROUND:Azacitidine as an effective epigenetic therapeutic agent has not been used as an aerosol form to treat lung cancer patients. We aerosolized clinical grade azacitidine (Aza), optimized the formulation, and studied its pharmacokinetics and toxicity in mice. METHODS:Extrusion-precipitation method and DNA methy...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2015.09.005
更新日期：2016-05-01 00:00:00
abstract：:We present a rare case of recurrent multiple lesions of bronchial epithelial-myoepithelial carcinoma in a 74-year-old man treated with local resection. Two cellular types were found: epithelial cells and myoepithelial cells. The patient remains asymptomatic at 4-years of follow-up, supporting the fact that epithelial-...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/CLC.2007.n.020
更新日期：2007-05-01 00:00:00
abstract：:Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic dermatologic side effects. Skin rash is the dose-limiting factor for all EGFR inhibitors and is usually dose related and reversible. Microbiologic stains and cultures from skin rash usually do not show an infectious cause. We re...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/CLC.2008.n.010
更新日期：2008-01-01 00:00:00
abstract：INTRODUCTION:To prospectively evaluate the frequency and spectrum of incidental findings (IF) in a 5-year lung cancer screening program with low-dose spiral computed tomography (CT) and to estimate the additional costs of their imaging workup incurred from subsequent radiologic follow-up evaluation. MATERIALS AND METH...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2012.05.005
更新日期：2013-03-01 00:00:00
abstract：OBJECTIVE:The objective of this study is to externally validate the 8th Edition of the Tumor, Node, and Metastasis staging system and its updated T descriptors in patients with non-small cell lung cancer with N3 disease. METHODS:Data were extracted from the Surveillance, Epidemiology, and End Results database. Chi-squ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2017.05.009
更新日期：2017-11-01 00:00:00
abstract：INTRODUCTION:Non-small-cell lung cancer (NSCLC) patients harboring ALK or ROS1 rearrangements invariably acquire resistance to the first- and second-generation tyrosine kinase inhibitors (TKIs), most notably ALK G1202R and ROS1 G2032R. Lorlatinib, a novel third-generation TKI, produced remarkable results from the first...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2018.12.020
更新日期：2019-05-01 00:00:00
abstract：:Active tumor immunotherapy may provide hope for patients with non-small-cell lung cancer (NSCLC) because, in more than 20 years, current therapies have yet to change mortality statistics. Creating an efficacious vaccine involves selection of important tumor antigens and formulation of their immunogenic epitopes into a...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/clc.2008.s.003
更新日期：2008-02-01 00:00:00
abstract：INTRODUCTION:We set out to investigate whether volumetric tumor measurements allow for a prediction of treatment response, as measured by patient survival, in patients with advanced non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS:Patients with nonresectable NSCLC (stage III or IV, n = 100) who were repeatedl...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2013.11.001
更新日期：2014-03-01 00:00:00
abstract：BACKGROUND:Malignant pleural effusion (MPE) has a profound impact on quality of life and survival in patients with lung cancer. Identification of the factors within the tumor and its environment that mediate MPE is still lacking. PATIENTS AND METHODS:Intratumoral microvessel density (MVD), endothelial cell and pericyt...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2013.06.007
更新日期：2013-11-01 00:00:00
abstract：INTRODUCTION:For patients with T1 or T2 N0 M0 small-cell lung cancer (SCLC), lobectomy followed by chemotherapy is the standard of care. However, because of its tendency for early dissemination, patients are often treated with concurrent chemo-radiation without surgery. This study was conducted to evaluate the utilizat...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2019.07.013
更新日期：2020-03-01 00:00:00
abstract：INTRODUCTION/BACKGROUND:The aim of this study was to identify imaging-based predictors of progression in patients treated with SABR for stage I NSCLC. PATIENTS AND METHODS:Between March 2003 and December 2012, 117 patients with stage I NSCLC meeting our study criteria were treated with SABR at Stanford University. Med...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2013.12.011
更新日期：2014-07-01 00:00:00
abstract：BACKGROUND:The optimal timing of thoracic radiation therapy (RT) in relation to chemotherapy is unknown in the treatment of nonmetastatic small cell lung cancer (SCLC). We analyzed the National Cancer Data Base (NCDB) to assess the effect on overall survival (OS) of RT timing with chemotherapy for patients with SCLC. ...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2016.07.009
更新日期：2017-03-01 00:00:00
abstract：:Novel therapies have been added to the treatment arsenal of physicians treating lung cancer in recent years. Most promising are agents that target the major pathways involved in cancer evolution, mostly proliferation and angiogenesis. Some of these treatments have been shown to synergize with traditional chemotherapy ...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/CLC.2008.s.014
更新日期：2008-01-01 00:00:00
abstract：INTRODUCTION:The aim of the study was to investigate the efficacy and tolerability of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in combination with pemetrexed/cisplatin in patients with stage IIIB to IV primary nonsquamous non-small-cell lung cancer and wild type V-Ki-ras2 Kir...
journal_title：Clinical lung cancer
pub_type： 杂志文章,随机对照试验
doi：10.1016/j.cllc.2015.05.009
更新日期：2015-11-01 00:00:00
abstract：BACKGROUND:Serum tumor markers are considered a negative prognostic factor in early-stages NSCLC but its role in advanced disease is controversial. The aim of this study is to analyze the prognostic value of tumor markers in advanced NSCLC. PATIENTS AND METHODS:Two hundred and seventy seven patients diagnosed in our i...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2011.03.019
更新日期：2011-05-01 00:00:00
abstract：PURPOSE:We conducted a phase I trial of the topoisomerase I inhibitor topotecan for the purpose of determining the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of topotecan when administered weekly to patients with advanced non-small-cell lung cancer. PATIENTS AND METHODS:Twelve patients with s...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.3816/CLC.2010.n.035
更新日期：2010-07-01 00:00:00
abstract：:Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor (EGFR) mutations (ie, exon 19 deletions and exon 21 L858R substitution) and anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers of adenocarcinoma...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.1016/j.cllc.2016.05.016
更新日期：2016-11-01 00:00:00
abstract：:This article describes the treatment rationale and study-related procedures for the A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small-Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL) st...
journal_title：Clinical lung cancer
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1016/j.cllc.2012.06.007
更新日期：2012-11-01 00:00:00
abstract：:During the past decade, the recognition of an ever-expanding list of driver oncogenic mutations in non-small-cell lung cancer has resulted in rapid therapeutic advances. Since the first description of the echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) rearrangement in 4% of case...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.1016/j.cllc.2016.05.006
更新日期：2016-11-01 00:00:00
abstract：:The treatment of lung cancer--small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC)--is a significant challenge in oncology. The best reported median survival remains near 1 year in advanced NSCLC despite several decades of steady improvement and extensive research with traditional chemotherapy drugs an...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/clc.2005.s.002
更新日期：2005-09-01 00:00:00
abstract：:Traditionally, non-small-cell lung cancer (NSCLC) is not thought of as an immunosensitive malignancy. However, recent clinical results with GVAX, a granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transduced autologous tumor vaccine, may suggest otherwise. This review summarizes immune-induced activity c...
journal_title：Clinical lung cancer
pub_type： 杂志文章,评审
doi：10.3816/clc.2003.n.027
更新日期：2003-11-01 00:00:00
abstract：INTRODUCTION:The effect of local therapy (LT) for oligoprogressive epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) has not been well established. Forty-six patients with stage IIIB/IV EGFR-mutated NSCLC were treated by LT and continuing tyrosine kinase inhibitors (TKIs) for oligoprogr...
journal_title：Clinical lung cancer
pub_type： 杂志文章
doi：10.1016/j.cllc.2017.04.002
更新日期：2017-11-01 00:00:00
